Antabio Turns to VCs for $7.3M in Financing

Présentation


Anthony Paronneau and Laetitia De Dinechinadvised Antabio SAS, a French biopharmaceutical company developing novel ways to treat drug-resistant infections, on a $7.3 million financing with subscriptions from a number of venture capital and investment funds.